Startup | May 18, 2022
Mental wellness startup Lissun targets phygital presence in over 25 cities this year
The centres will be located in Tier I and Tier II cities
The centres will be located in Tier I and Tier II cities
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Covaxin was earlier approved for children 12-18 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Subscribe To Our Newsletter & Stay Updated
